RecruitingNCT05962216
Real-world brexpiprazole use in schizophrenia and depression
About this title
Read the official source — NCT05962216Observational studyAges 18–65China
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Hong KongSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: July 1, 2023
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 40
- Sponsor
- Dr. Albert Kar-Kin Chung
- Sponsor type
- Individual investigator
- Study type
- Observational
- Intervention type
- Drug
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05962216
- Official title
Show the full official title
Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders: a Naturalistic Non-interventional Prospective Follow-up Study
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Hong Kong, Hong Kong · China
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Dr. Albert Kar-Kin Chung.
Does this study involve medication?
Yes. The study involves medication, including Brexpiprazole.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
